Virpax Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jay Dhaliwal

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jay Dhaliwal (36 yo)

less than a year

Mandato

Mr. Jatinder Dhaliwal, also known as Jay, serves as Chief Executive Officer of Virpax Pharmaceuticals, Inc since October 06, 2024 and serves as its Director since October 06, 2024. He serves as a Director...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jatinder Dhaliwal	CEO & Director	less than a year	Nessun dato	Nessun dato
Gary Herman	Independent Director	less than a year	Nessun dato	Nessun dato
Judy Su	Independent Director	less than a year	Nessun dato	Nessun dato
Katharyn Field	Independent Director	less than a year	Nessun dato	Nessun dato

0.3yrs

Durata media

39.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di VRPX non è considerato esperto (durata media del mandato 0.3 anni), il che suggerisce un nuovo consiglio.

Virpax Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Virpax Pharmaceuticals, Inc. Announces CEO Changes

High number of new and inexperienced directors

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Recent updates

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million.

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

High number of new and inexperienced directors

Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price

New major risk - Revenue and earnings growth

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Shareholder dilution

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million.

Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1)

New major risk - Financial position

Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2)

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing

Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review

Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Novvae Pharmaceuticals Announces Executive Appointments

Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals

Virpax Pharmaceuticals, Inc. Announces Update on Litigation

Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method

New major risk - Market cap size

Virpax Pharmaceuticals, Inc. Announces CFO Changes

New minor risk - Share price stability

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023

Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director

Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology

Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar

Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022

Chairman & CEO recently bought US$102k worth of stock

Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324

Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm

Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee

Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Chairman & CEO recently bought US$100k worth of stock

Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd.

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million.

Virpax: Targeting Pain At Its Source

Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta

Virpax Pharmaceuticals shares surge on Envelta IND update

Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm)

Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million.

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media